Literature DB >> 3261674

Serum aminoterminal type III procollagen peptide in inflammatory and degenerative rheumatic disorders.

K Hørslev-Petersen1, K D Bentsen, P Junker, F K Mathiesen, T M Hansen, I Lorenzen.   

Abstract

Measurement of the aminoterminal type III procollagen peptide in serum has been suggested as a marker of the biosynthesis of collagen type III, a major connective tissue component in repair processes. In the present study the propeptide level correlated with the inflammatory synovial mass in rheumatoid arthritis and osteoarthritis. This implies that the propeptide level reflects the collagen type III synthesis occurring in the synovial repair processes, whether they were caused by inflammatory or degenerative rheumatic disorders. Physical activity did not enhance the transition of the propeptide from the synovial fluid or the inflamed synovial membrane to the blood. Normal serum propeptide values were observed in most patients with ankylosing spondylitis and degenerative diseases of the spine. This may reflect the lower amount of inflammatory tissue in these diseases and hence the sensitivity of the assays.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261674     DOI: 10.1007/bf02284058

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  N-terminal procollagen peptide and beta 2-microglobulin in synovial fluids from inflammatory and non-inflammatory joint diseases.

Authors:  A M Gressner; H H Neu
Journal:  Clin Chim Acta       Date:  1984-08-31       Impact factor: 3.786

3.  Aminoterminal propeptide of type III procollagen in serum in alcoholic liver disease.

Authors:  O Niemelä; L Risteli; E A Sotaniemi; J Risteli
Journal:  Gastroenterology       Date:  1983-08       Impact factor: 22.682

4.  Double-blind trial of levamisole, penicillamine and azathioprine in rheumatoid arthritis. Clinical, biochemical, radiological and scintigraphic studies.

Authors:  P Halberg; M W Bentzon; O Crohn; I Gad; O Halskov; J Heyn; M Ingemann; P Junker; I Lorenzen; I Møller
Journal:  Dan Med Bull       Date:  1984-10

Review 5.  The collagens of the joint.

Authors:  S Gay; R E Gay; E F Miller
Journal:  Arthritis Rheum       Date:  1980-08

6.  Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine.

Authors:  K Hørslev-Petersen; K D Bentsen; A Engström-Laurent; P Junker; P Halberg; I Lorenzen
Journal:  Ann Rheum Dis       Date:  1988-02       Impact factor: 19.103

7.  Serum aminoterminal type III procollagen peptide. Relation to biosynthesis of collagen type III in experimentally induced granulation tissue in rats.

Authors:  K Hørslev-Petersen; K Y Kim; L R Pedersen; K D Bentsen; N Uldbjerg; H Oxlund; C Garbarsch; E G Hahn; D Schuppan; I Lorenzen
Journal:  APMIS       Date:  1988-09       Impact factor: 3.205

8.  Radioimmunoassay for type III procollagen peptide and its application to human liver disease.

Authors:  H Rohde; L Vargas; E Hahn; H Kalbfleisch; M Bruguera; R Timpl
Journal:  Eur J Clin Invest       Date:  1979-12       Impact factor: 4.686

9.  Serum and urine analysis of the aminoterminal procollagen peptide type III by radioimmunoassay with antibody Fab fragments.

Authors:  H Rohde; I Langer; T Krieg; R Timpl
Journal:  Coll Relat Res       Date:  1983-09

10.  Serum amino-terminal type III procollagen peptide in rheumatoid arthritis. Relationship to disease activity, treatment, and development of joint erosions.

Authors:  K Hørslev-Petersen; K D Bentsen; P Junker; I Lorenzen
Journal:  Arthritis Rheum       Date:  1986-05
View more
  4 in total

1.  Differential patterns of PMN-elastase and type III procollagen peptide in knee joint effusions due to acute and chronic sports injuries.

Authors:  K A Riel; M Jochum; P Bernett; H Fritz
Journal:  Klin Wochenschr       Date:  1991-11-15

2.  Synovial fluid and serum concentrations of aminoterminal propeptide of type III procollagen in healthy volunteers and patients with joint disease.

Authors:  M Sharif; E George; P A Dieppe
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

3.  The aminoterminal-type-III procollagen peptide and proteoglycans in serum and synovial fluid of patients with rheumatoid arthritis or reactive arthritis.

Authors:  K Hørslev-Petersen; T Saxne; D Haar; B S Thomsen; K D Bentsen; P Junker; I Lorenzen
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

4.  Type III collagen metabolism in soft tissue sarcomas.

Authors:  T A Wiklund; I Elomaa; C P Blomqvist; L Risteli; J Risteli
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.